Afinitor 2019 U.S. PROMOTIONAL AUDIT REPORT

Published July 2020 • 31 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Afinitor through reportable promotional activity in 2019 and how does this compare to its peer set in the Astrocytoma, Breast Cancer, Neuroendocrine Tumors, and Renal Cancer markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Novartis’s depth of coverage vary within key specialties (e.g., Neurology, Hematology/Oncology, Urology, Nephrology, Pediatric Medicine, Medical Oncology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Afinitor throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Afinitor in 2019?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 2,100 paid interactions across 1,400 physicians made on behalf of Afinitor were carefully examined to support our analysis. In addition, interaction data from 28 peer products (e.g. Abraxane, Avastin, Bavencio, Cabometyx, Halaven, Herceptin, Ibrance, Inlyta, Kadcyla, Kanjinti, Keytruda, Kisqali, Lenvima, Lutathera, Lynparza, Mvasi, Nerlynx, Nexavar, Ogivri, Opdivo, Perjeta, Piqray, Somatuline Depot, Sutent, Talzenna, Tecentriq, Verzenio, and Votrient ) was leveraged to provide benchmarking and market insights.